Opinion

Video

Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.

Video Player is loading.
Current Time 0:00
Duration 5:30
Loaded: 2.98%
Stream Type LIVE
Remaining Time 5:30
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Video content above is prompted by the following:

  • What clinical factors do you consider for patients with R/R DLBCL who are primary refractory or experience early relapse in determining transplant eligibility?
    • When CAR T-cell therapy is the best option for your patient, how does the manufacturing process time line affect your decisions?
      • Are most community oncologists referring to CAR T-cell centers or keeping their patients?
      • How early are patients being referred to your center (eg, second-line, third-line)?
      • When do you initiate the collection/production process?
      • What is the primary impetus for early referral?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Content